6IRA.F IRLAB THERAP. AB A

Healthcare Biotechnology Frankfurt Exchange
0.1987 EUR
Close of Nov 11, 2026
0.1048 0.2090
Market cap
EUR 29.5M
P/E
-
P/B
3.14x
ROE
-20.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6IRA.F undervalued?

Graham number

The Graham number of IRLAB THERAP. AB A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IRLAB THERAP. AB A fundamental analysis

No fundamental analysis for IRLAB THERAP. AB A yet.

IRLAB THERAP. AB A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IRLAB THERAP. AB A

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pirepemat (IRL752), which is in a Phase IIB clinical trial to reduce the risk of fa…

Full company profile